Galera completes $350M PIPE financing; merger with Obsidian expected to close Aug 3, 2026

Galera Therapeutics, Inc.

Closed $350M PIPE sale of Series C Preferred Stock to qualified investors on July 31, 2026.
Merger with Obsidian expected to close August 3, 2026, subject to customary conditions.
Pre-Closing Distribution of CVRs to common stockholders: record date July 31, distribution date Aug 6.
Each CVR entitles holder to net proceeds from future disposition of tilarganine and GC4711/GC4419 assets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.